Protein engineering responses to the COVID-19 pandemic
- PMID: 35533563
- PMCID: PMC9075828
- DOI: 10.1016/j.sbi.2022.102385
Protein engineering responses to the COVID-19 pandemic
Abstract
Antigen design guided by high-resolution viral glycoprotein structures has successfully generated diverse vaccine candidates for COVID-19. Using conjugation systems to combine antigen design with computationally optimized nanoparticles, researchers have been able to display multivalent antigens with beneficial substitutions that elicited robust humoral immunity with enhanced neutralization potency and breadth. Here, we discuss strategies that have been used for structure-based design and nanoparticle display to develop COVID-19 vaccine candidates as well as potential next-generation vaccine candidates to protect against SARS-CoV-2 variants and other coronaviruses that emerge into the human population.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement J.S.M. is an inventor on U.S. patent no. 10, 960, 070 (“Prefusion Coronavirus Spike Proteins and Their Use”) and U.S. patent application no. 62/972,886 (“2019-nCoV Vaccine”). C.-L.H. and J.S.M. are inventors on U.S. patent application no. 63/032,502 (“Engineered Coronavirus Spike (S) Protein and Methods of Use Thereof”) and U.S. patent application no. 63/188,813 (“Stabilized S2 Beta-coronavirus Antigens’’).
Figures
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
